ARTICLE | Clinical News
Liraglutide: Phase III data
June 9, 2008 7:00 AM UTC
Top-line data from the 26-week Phase III LEAD-6 trial in 464 patients showed that once-daily liraglutide met the primary endpoint of a significant improvement in baseline HbA1c levels vs. twice-daily ...